[REVISION HISTORY]
Clinical development of diabetic foot infection treatments
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-08-25 23:14 UTC → 2026-08-26 22:05 UTC ·
added
removed
Biotechnology companies are advancing clinical trials for topical gel treatments targeting diabetic foot infections and ulcers. In Australia, Recce Pharmaceuticals has received ethics committee approval to expand its Phase 3 clinical trial for RECCE 327 Topical Gel (R327G). The expanded protocol includes a randomized, active-controlled study arm involving 208 patients to compare the gel against four physician-selected antibiotics. The trial also incorporates wound imaging via digital photography to provide objective measurements. Concurrently, US-based Lakewood-Amedex Biotherapeutics is preparing for a Phase 2a clinical trial of Nu-3, a topical Bisphosphocin gel. This treatment is designed to combat infectious diseases and antibiotic-resistant bacterial strains by physically disrupting bacterial membranes. Lakewood-Amedex was recently named a ‘Featured Company’ by B2i Digital, a designation intended to help the firm present its clinical programs and scientific milestones to a broader network of retail and institutional market participants.
Versions
- 2026-08-26 22:05 UTC Clinical development of diabetic foot infection treatments
- 2026-08-25 23:14 UTC Clinical development of diabetic foot infection treatments
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.